Kornimate/medical-research-clean huggingface dataset:
surveillance of summer febrile syndromes of viral origin in south of france

Conditions: Summer Febrile Syndromes of Viral Origin

Summary: the aim is to document viral etiologies of isolated fevers and inlfuenza-like syndromes during summertime in south of france in order to better understand the role of known vector-borne viruses such as toscana virus, west nile virus during seasonal activity of the arthropod vector. in each of the four cities, a network of general practitioners will be associated in the project to recruit patients who are not hospitalized. the combined involvement of infectious disease specialists and general practitioner will augment the range of patients (mild disease and sever cases) in the study.


Eligibility criteria:
inclusion criteria: * old: equal to or higher than 5 years living in the south of france, without voyage abroad in the 2 weeks preceding inclusion presenting a fever or a syndrome pseudogripal since less than 7 days without diagnostic orientation nor infectious pathology of body, * affiliated with a mode of social security * after obtaining free and informed of the written assent exclusion criteria: * subject whose adhesion with the protocol is improbable according to the investigator * expectant mother * subject taking part in another clinical trial or in period of exclusion of a preceding clinical trial infectious * pathology of body requiring a specific treatment * discovered after inclusion d' a pregnancy
national cohort of patients co-infected with hepatitis b and delta viruses

Conditions: Hepatitis D, Chronic; Hepatitis B, Chronic

Summary: this is a multicentre observational study with prospective and retrospective data collection and retrospective data collection and biological collection from patients with hbv/hdv co-infection.

this is an observatory for patients co-infected with hepatitis b and delta viruses. patients will be monitored according to the usual recommendations, depending on their status: * patients who have never received specific treatment for hepatitis delta (untreated or receiving treatment with peginterferon alpha 2a alone) will be monitored according to current recommendations, once every 6 months; * patients treated or having been treated with a specific hepatitis delta treatment will be monitored according to the compassionate access protocol or according to the recommendations of the amm during treatment and according to routine follow-up after the end of treatment. participation in research entails the following additional procedures for patients, for each line of treatment, where applicable: * samples for the biobank, * self-administered questionnaires. in addition, as sub-studies are planned on sub-groups of patients, these sub-studies may involve additional constraints/interventions

Eligibility criteria:
inclusion criteria: * age \> 18 years, * presenting a chronic hdv infection (positive serology), * who gave his written informed consent before any intervention and the day of inclusion at the latest, * affiliated to health insurance or to the "aide médicale d'etat" (request for exemption pending). exclusion criteria: * patient participating in another biomedical research with an exclusion period ongoing at inclusion, * vulnerable patient (minor, adults legally protected: under judicial protection, guardianship, or supervision, persons deprived of their liberty). * patients with predictable difficulties of follow-up according to the investigator.

Keywords: safety efficacy evolution treatment
evis - ex-vivo assessment of t-lymphocyte homing in primary pancreatic cancer

Conditions: Pancreatic Cancer

Summary: this is a single-centre, prospective, non-randomised research study. the research team will investigate the feasibility of assessing primary human pancreatic tissue for changes to t lymphocyte function and localisation in the presence and absence of amd3100.

pancreatic cancer is the fourth leading cause of cancer-related deaths in western countries. it is a lethal disease that typically presents late, metastasises early and is resistant to conventional treatments such as radiation and chemotherapy. in 2012 there were 8700 deaths in the uk from pancreatic cancer, making it the fifth most common cause of cancer-related death. current therapeutic strategies are aimed at extending survival as well as improving symptoms and quality of life, but although conventional chemotherapeutic agents have achieved modest clinical benefit, the need for novel therapies is great. this study proposes to extend our pre-clinical studies to develop an ex-vivo assay for the assessment of amd3100 effectiveness in human samples. the research team will investigate the feasibility of assessing primary human pancreatic tissue for changes to t lymphocyte function and localisation in the presence and absence of amd3100 through obtaining a blood sample and fresh pancreatic tissue intra-operatively from pancreatic tumours located in the head of the pancreas.

Eligibility criteria:
inclusion criteria: * patients with primary pancreatic adenocarcinoma who are undergoing pancreaticoduodenectomy (whipple's) resection. * patients who are over 18 years of age at the time of signing the informed consent form and who are physically and mentally capable of consenting. * willing and able to comply with study procedures. exclusion criteria: • any condition or abnormalities that in the judgment of the investigator/surgeon/ histopathologist would place the patient at undue risk.
effects of oral l-arginine on chronic hypertension in pregnancy

Conditions: Hypertension in Pregnancy

Summary: the purpose of this study is to evaluate the effects of oral l-arginine in pregnant women with chronic hypertension.


Eligibility criteria:
inclusion criteria: * pregnant women between 18-20 week of gestation with chronic hypertension exclusion criteria: * maternal or fetal disease

Keywords: chronic hypertension in pregnancy chronic hypertension
strategies for antithrombotic treatment following transcatheter edge-to-edge repair in patients with an indication for oral anticoagulant

Conditions: Mitral Regurgitation

Summary: mitral regurgitation (mr) is the most common valvular heart disease, affecting approximately 24.2 million people worldwide (with a higher prevalence in older age groups). transcatheter edge-to-edge repair (teer) is now a well-established strategy in high-risk patients with mr. globally, over 250,000 patients have benefited from the teer technique.studies have shown that patients with severe mitral regurgitation exhibit a high prevalence of atrial fibrillation (af), reaching up to 63%, which is an indication for long-term oral anticoagulation (oac) therapy. however, no dedicated study has prospectively evaluated different antithrombotic strategies following teer in patients with an indication for oac. current guidelines do not provide any recommendations for the antithrombotic management of teer. consequently, considerable treatment variation exists in clinical studies and practice. the investigators will conduct a multicenter, open-label randomized trial to compare different antithrombotic strategies following teer in patients who have an indication for oac.


Eligibility criteria:
inclusion criteria: * patients who had undergone successful teer (defined as techinal success according to mvarc ); * need for long-term oral anticoagulation; * ability to understand the requirements of the trial and willingness to comply with the trial protocol procedures; * providing written informed consent form； * women of childbearing potential must use an acceptable method of contraception from signing the informed consent form until the date of the last dose of antithrombotic drug; * the heart team agrees on the antithrombotic strategies. exclusion criteria: * severe renal impairment (creatinine clearance rate\<15ml/min or on dialysis)； * postoperative persistent bleeding (overt bleeding either associated with a drop in the hemoglobin of 3.0 g/dl or requiring transfusion of 3 u of whole blood or packed red blood cells) or occurrence of vascular complications； * platelet count ≤ 30 ×10\^9/l； * need for reoperation； * history of intracranial or intracerebral hemorrhage； * history of gastrointestinal ulcers or hemorrhage； * any hepatic disease associated with coagulopathy (child-pugh b or c); * allergy, intolerance or contraindication to oral anticoagulation or antiplatelet drug; * history of cerebrovascular event or transient ischemic attack within the past 6 weeks; * current antiplatelet therapy； * patients who have participated in another drug or device investigational study within the past 30 days； * life expectancy \<12 months； * pregnant or breastfeeding women。

Keywords: transcatheter edge-to-edge repair (teer) mitral regurgitation cardiovascular diseases embolism and thrombosis bleeding aspirin rivaroxaban antithrombotic treatment oral anticoagulation platelet aggregation inhibitors stroke myocardial infarction
traditional three-incision esophagectomy versus minimally invasive thorascopic and laparoscopic esophagectomy

Conditions: Esophageal Cancer

Summary: esophageal carcinoma is an aggressive malignancy with poor prognosis. surgical resection remains the most effective method for this malignant disease. vats esophagectomy has become more and more popular in china and around the world. although vats esophagectomy has been proven to be effective in preventing respiratory complications, there is still no ample evidences to demonstrate that vats esophagectomy is as effective as traditional three-incision esophagectomy in lymph node dissection and is equal or superior in long-term survival. the purpose of this large scale prospective observational study is to compare the minimally invasive thorascopic/laparoscopic esophagectomy with traditional three-incision esophagectomy in lymph node dissection, postoperative recovery, postoperative complications, and long-term survival.

esophageal carcinoma is an aggressive malignancy with poor prognosis,for these patients, radical esophagectomy is the cornerstone of multimodality treatment with curative intent. transthoracic esophagectomy is the preferred surgical approach worldwide allowing for en-bloc resection of the tumor. however, the percentage of cardiopulmonary complications associated with the traditional three-incision esophagectomy is high.recent studies have shown that the minimally invasive thorascopic and laparoscopic esophagectomy is at least equivalent to the open transthoracic approach for esophageal cancer in terms of short-term oncological outcomes,including reduced blood loss, shorter icu stay,and lower pulmonary complication rate, but the evidence is not ample because the sample size is not enough.the objective of this study is to compare the efficacy, perioperative complications, lymph node dissection and long term survival between the thoracic esophageal cancer patients treated by minimally invasive thorascopic/laparoscopic esophagectomy and open transthoracic esophagectomy by three incisions.

Eligibility criteria:
inclusion criteria: 1. patients with histologically proven squamous cell esophageal cancer, without any previous anti-tumor therapy; 2. preoperative clinical tnm stage:ct1b-3n0-1m0; 3. adequate cardiopulmonary, liver, brain and kidney function which can tolerate the esophagectomy either via traditional tree-incision or minimally invasive thorascopic/laparoscopic esophagectomy; 4. preoperative assessment by ct and eus is fit for minimally invasive thorascopic/laparoscopic esophagectomy; 5. willing to participate the clinical trial and sign the informed consent before being enrolled into clinical trail. exclusion criteria: 1. previous use of anti-cancer therapy; 2. preoperative clinical tnm stage: n2-3 or m1; 3. inadequate cardiopulmonary,liver, brain and kidney function for surgery; 4. previous malignancy history; 5. unwilling to participate the clinical trial and refuse to sign informed consent.
immediate exercise-induced hypoalgesia in patients with chronic low back pain

Conditions: Low Back Pain

Summary: the main objective of this study is: • to evaluate the immediate hypoalgesic effect of an aerobic exercise session of different intensities in patients with chronic low back pain; the secondary objective is: • to explore whether pain intensity, level of physical activity, functionality, catastrophizing, kinesiophobia, anxiety and depression interfere with the immediate hypoalgesic effect of exercise.

there will be 3 groups of participants, an asymptomatic control group that will not perform any exercise and two groups of individuals with low back pain. one group will perform exercise at 90% vo2máx and the other at 60% vo2máx. all the three groups will be assessed at baseline for pressure pain threshold, pain intensity, pain phenotype, disability, kinesiophobia, catastrophizing, anxiety and depression, physical activity, and aerobic capacity. in addition, pressure pain threshold and pain intensity will also be assessed at post-intervention.

Eligibility criteria:
inclusion criteria: * all groups: * age between 18 and 65 years old * participants with low back pain: * non-specific lbp (defined as pain between the costal margins and the inferior gluteal folds, which is usually accompanied by painful limitation of movement and may be associated with pain referred down to the leg) exclusion criteria: * all groups: * presence of pathology of the nervous system, cardiovascular or carcinogenic, rheumatic diseases (for example, rheumatoid arthritis), fibromyalgia, previous history of lumbar surgery, medication that affects or alters heart rate, any contraindication to exercise and pregnancy.
swiss study on subarachnoid hemorrhage

Conditions: Subarachnoid Hemorrhage; Intracranial Aneurysm

Summary: this registry was created to assess management parameters of patients treated for aneurysmal subarachnoid hemorrhage in switzerland. all swiss hospitals with a neurosurgery department, an intensive care unit and an interventional neuroradiology team that treat neurovascular emergencies participate in the registry. clinical parameters are entered into a common database. this database will provide (1) a nationwide assessment of the current standard of care and (2) the outcomes for patients in switzerland including neuropsychological assessments.

overview: the management of aneurysmal subarachnoid hemorrhage (asah) in switzerland has not been assessed on a national level to date. the investigators united all comprehensive neurovascular care centres in switzerland to create a registry for asah. this registry helps collect clinical and management data from different centres and pools it in one common database. it may provide referring caregivers and healthcare providers with a critical tool to assess the quality of care in a disease which has a high socio-economic burden. moreover, it may serve as a tool to foster scientific collaboration and address a number of remaining questions about the management of asah in the future. regarding sah, data from the federal statistics bureau of switzerland are based strictly on icd-10 codes provided by hospitals and show an estimate of 13 per 100,000 in a population of roughly 8 million (http://bfs.admin.ch). these numbers, however, are not referring to aneurismal sah exclusively and thus exceed the numbers which the investigators expect to obtain. the goal is to obtain complete recruitment of sah patients throughout switzerland, and the goal is therefore that assessment of incidence will be performed later on. data management: data is entered into a central online database created by the secutrial platform. this platform is provided by the university hospital of geneva's clinical research unit. the database disposes of an audit-trail capacity. local principal investigators are responsible for data-cross check and quality management. source data verification is performed by investigators on site who address missing data. regular meetings are held to discuss data patency. the platform automatically provides a report on recruitment progress.

Eligibility criteria:
inclusion criteria: - patients admitted with a proven diagnosis of aneurysmal subarachnoid hemorrhage. exclusion criteria: - patients in whom the source of haemorrhage could not be identified (angiogram-negative sah) or sah with other causes than cerebral aneurysms.

Keywords: subarachnoid hemorrhage intracranial aneurysm ruptured intracranial aneurysm neurosurgery interventional neuroradiology neurointensive care medicine switzerland
comparative effects of strain-counterstrain and muscle energy techniques on neck pain and functional disability in patients with cervicogenic headache

Conditions: Cervicogenic Headache

Summary: the primary objective of this study is to compare effects of scs and mets on reduction of neck pain intensity and improvement in functional disability in individuals with cgh. the secondary objective is to assess the impact of both techniques on rom in cervical spine


Eligibility criteria:
inclusion criteria: * participants who fulfill the criteria of international headache society. exclusion criteria: * participants who have cervicogenic headache after cervical injury or head surgery.

Keywords: cgh scs mets
study on the contribution of the genetic tumor profile obtained by circulating tumor dna analysis in the multidisciplinary molecular biology meeting of eastern paca

Conditions: Neoplasm Malignant

Summary: this study will evaluate the diagnostic performance of liquid biopsy for identifying molecular abnormalities among patients managed by the multidisciplinary molecular biology meeting. the gold standard considered in this study is the solid biopsy.


Eligibility criteria:
inclusion criteria: * over 18 years old. * advanced-stage malignant solid tumor managed in a non-curative context. * patient eligible for multidisciplinary molecular biology meeting with available archived tumor material (frozen or ffpe block, less than 5 years old) or a biopsiable tumor lesion. * performance status of 0 or 1. * patient able to read, write, and understand the french language. * patient has read the information sheet and signed the informed consent. * patient has social security coverage. exclusion criteria: * previous or concurrent cancer diagnosed or treated within the last 5 years, except for in situ carcinoma of the cervix, basal cell or squamous cell carcinoma of the skin, and adequately treated in situ carcinoma of the bladder. * severe or uncontrolled systemic disease. * any condition which, in the investigator's judgment (geographical, social, or psychological factors, etc.), makes the patient unable to comply with study follow-up and procedures. * patient considered a vulnerable person; vulnerable persons are defined in articles l1121-5 to l1121-8: * pregnant women, women in labor, and breastfeeding mothers, * persons deprived of liberty by judicial or administrative decision, individuals hospitalized without consent under articles l. 3212-1 and l. 3213-1 who do not fall under the provisions of article l. 1121-8, * persons admitted to a healthcare or social institution for reasons other than research, * adults unable to give their consent.

Keywords: liquid biopsy
study of aripiprazole in patients with acute bipolar mania

Conditions: Bipolar Disorder

Summary: the purpose of this research study is to confirm the safety and effectiveness of aripiprazole therapy over 12 weeks in subjects with bipolar disorder experiencing symptoms of mania.


Eligibility criteria:
inclusion criteria: * subjects with bipolar i disorder and a diagnosis of acute mania will be considered for this study.

Keywords: bipolar mania
gum remote testing v4.0

Conditions: HIV Infections; Syphilis Infection; Hepatitis B and Hepatitis C

Summary: capillary blood sample results are compared to venous blood results

capillary blood samples can be taken by patients from their own finger without requiring a healthcare professional to take a blood sample. samples taken this way can be posted from home. this crucially avoids visits to the clinic or hospital to have blood samples taken. it would reduce the burden on healthcare professionals and is often preferred by patients. it is important to demonstrate that the results of an analysis performed on capillary blood samples are equivalent to the analysis of a standard venous sample. this study aims to collect, in parallel to a standard venous blood sample, a capillary blood sample taken by the participant which is then added to specially designed filter paper (dried plasma spot sample) or other collection devices. parallel analysis of paired samples will then allow the investigators to assess if results measured in samples taken using the two methods are similar. the investigators will recruit 40 participants for each collection device to this study. it is important to obtain a range of positive and negative results from the study participants, and from stored samples and quality control material.

Eligibility criteria:
inclusion criteria: * adults * able and willing to provide informed consent. * already having a venous blood sample for clinical care exclusion criteria: * failure to consent
the impact of intraoperative systemic lidocaine infusion on chronic postoperative pain after video-assisted thoracic surgery (vats)

Conditions: Lung Cancer(Primary, Metastatic); Benign Lung Mass Requiring Operation

Summary: systemic lidocaine infusion may improve the patients' chronic post surgical pain after video-assisted thoracic surgery


Eligibility criteria:
inclusion criteria: * age between 20 and 65 years * asa class 1 and 2 * patients who are scheduled for video-assisted thoracic surgery exclusion criteria: * allergy to local anesthetics or contraindication to use of lidocaine * pregnancy * severe cardiovascular disease * renal failure * liver failure * neurologic and psychologic disease * chronic treatment with analgesics or chronic pain patients * previous history of thoracic surgery (open or video-assisted) * patients' refusal

Keywords: systemic lidocaine postoperative pain video-assisted thoracic surgery vats